Genitourinary Cancer in 2022 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Daniel Petrylak, MD
Yale University, New Haven, CT, USA
Faculty Members
Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA
Karim Fizazi, MD, PhD
Institut Gustave Roussy, Villejuif, France
Thomas Powles, MBBS, MRCP, MD
Barts Cancer Centre, London, United Kingdom
Oliver Sartor, MD
Tulane University School of Medicine, New Orleans, LA, USA
Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, USA
José Pablo Maroto Rey, MD, PhD
Instituto de Urología Serrate & Ribal, Barcelona, Spain
Joaquim Bellmunt, MD, PhD
Harvard Medical School, Boston, MA, USA
Manuela Schmidinger, MD
University of Vienna, Vienna, Austria
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Early-Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
- Current Paradigms and Future Directions in Metastatic Bladder Cancer
- Evolving Paradigms for Metastatic RCC
- Neo/Adjuvant Treatment of RCC
- Current and Future Management of Non-clear Cell RCC
- Advances in Imaging Technologies for Genitourinary Cancers
- Treatment Paradigms for Advanced Prostate Cancer
- Investigational Therapies for Metastatic CRPC
